Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.39 EUR | -1.42% | +15.83% | +60.14% |
2023 | Medesis Pharma S.A. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
2023 | MEDESIS : Invest Securities confirms its recommendation | CF |
Business Summary
The company's portfolio includes a drug candidate used to optimize cancer radiotherapy, 2 drug candidates used in the treatment of neurodegenerative diseases (Alzheimer's disease and Huntington's disease) and 2 drug candidates used in the treatment of radioactive contamination following a civil or military nuclear accident (Plutonium decorporation and cesium decorporation).
Number of employees: 10
Sales per Business
EUR in Million | 2019 | Weight | 2020 | Weight | Delta |
---|---|---|---|---|---|
Biopharmaceutical
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | -9.35% |
Sales per region
EUR in Million | 2019 | Weight | 2020 | Weight | Delta |
---|---|---|---|---|---|
France
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | -9.35% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | - | 03-04-02 | |
Solene Guilliot
CTO | Chief Tech/Sci/R&D Officer | - | 20-12-31 |
Mario Alcaraz
SEC | Corporate Secretary | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | - | 19-06-11 | |
Robert Alonso
BRD | Director/Board Member | - | 22-10-26 |
Walt Linscott
BRD | Director/Board Member | 63 | 22-10-26 |
Olivier Connes
CHM | Chairman | - | 18-09-25 |
Director/Board Member | - | 15-06-29 | |
Cédric Navas
BRD | Director/Board Member | - | 18-09-25 |
Emmanuel Hebert
BRD | Director/Board Member | - | 19-06-11 |
Director/Board Member | - | 21-06-14 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 4,429,081 | 3,586,229 ( 80.97 %) | 0 | 80.97 % |
Company contact information
Medesis Pharma SA
L'Orée des Mas avenue du Golf
34670, Baillargues
+33 4 67 03 03 96
http://www.medesispharma.comSector
1st Jan change | Capi. | |
---|---|---|
+60.14% | 6.63M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- ALMDP Stock
- Company Medesis Pharma S.A.